Compare · LLY vs MLYS
LLY vs MLYS
Side-by-side comparison of Eli Lilly and Company (LLY) and Mineralys Therapeutics Inc. (MLYS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and MLYS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.35T, about 980.4x MLYS ($1.37B).
- LLY has been more active in the news (34 items in the past 4 weeks vs 16 for MLYS).
- LLY has more recent analyst coverage (25 ratings vs 11 for MLYS).
- Company
- Eli Lilly and Company
- Mineralys Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.35T
- $1.37B
- 1M return
- +21.13%
- -
- 1Y return
- +44.92%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 34
- 16
- Recent ratings
- 25
- 11
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- EVP & President, LLY Int'l Jonsson Patrik gifted 704 shares, decreasing direct ownership by 1% to 53,443 units (SEC Form 4)
- Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
- Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
- Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity
- President, Chair, and CEO Ricks David A gifted 23,538 shares (SEC Form 4)
- Treasury's Refunding Details Are Up Next as Five Large Companies Report Higher Revenue
- EVP, CS&PO & Pres. LRL Skovronsky Daniel gifted 119 shares, decreasing direct ownership by 0.07% to 159,953 units (SEC Form 4)
Latest MLYS
- Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026
- Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 10-Q filed by Mineralys Therapeutics Inc.
- Mineralys Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Mineralys Therapeutics to Participate in Upcoming Investor Conferences
- SEC Form 8-K filed by Mineralys Therapeutics Inc.
- Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026
- Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International
- Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026